AstraZeneca, in partnership with Secaro and ERM, is launching a Clean Heat Program to decarbonize industrial heat across its supply chain, aiming to reduce emissions and stabilize costs amid volatile natural gas prices. Industrial heat, a major source of emissions in pharmaceutical manufacturing, has been hard to decarbonize due to its complexity and cost, but recent geopolitical events have made clean alternatives economically viable. The program supports suppliers with data-driven pathways and financing options to adopt low-carbon heat solutions, enhancing supply chain resilience and reducing exposure to energy price shocks. This initiative reflects a strategic shift where clean heat is viewed not just as sustainability but as risk management and a competitive advantage.
T. Rowe Price emphasizes the growing risk of US market concentration in a few mega-cap stocks, now making up 32% of the S&P 500. The firm points to international equities as a promising alternative, noting they trade at a 23% forward P/E discount and...
AstraZeneca received a 'Strong Buy' rating following robust revenue growth in Q1 2026, driven by 16% and 15% increases in its Oncology and Rare Disease segments, respectively. Key drugs IMFINZI and ULTOMIRIS showed positive phase 3 trial results, ope...
